Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Lifesciences receives final approval from USFDA for Adapalene and Benzoyl Peroxide Topical Gel07-06-2022
07-06-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform that the Company is going to participate in Morgan Stanley India Summit 2022 on June 7, 2022 which is arranged virtually. There will be one one-on-one calls and one group call.06-06-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Lifesciences receives final approval from USFDA for Famotidine Tablets06-06-2022
Zydus Lifesciences Ltd - 532321 - Half Yearly Related Party Disclosure Under Regulation 23(9) Of The Listing Regulations
Half yearly Related Party Disclosure under regulation 23(9) of the Listing Regulations03-06-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Disclosures under SEBI PIT Regulations31-05-2022
Zydus Lifesciences Ltd - 532321 - Draft Letter Of Offer
Draft Letter of Offer for proposed buyback.30-05-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Disclosure under Insider Trading Regulations30-05-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Disclosure in prescribed Form 'C' under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015, received from Mr. Nitin Raojibhai Desai, Independent Director of the Company27-05-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
The Transcript of the Company's Q4 FY22 post results Investors' call held at 4:30 p.m. on May 20, 202226-05-2022